Post Profile






FDA widens holds on immunotherapy combination blood cancer trials

(Reuters) - U.S. health regulators stopped five blood cancer trials testing AstraZeneca Plc's immunotherapy Imfinzi in combination with Celgene Corp medicines from accepting new patients and halted another study entirely, the companies said on Thursday.
read more

share

Related Posts


How AstraZeneca cancer drug forecasts are set to rise

Health : Reuters: Health

LONDON (Reuters) - Sales forecasts for AstraZeneca's all-important new cancer immunotherapy drug Imfinzi are set to rise after the drugmaker received an unexpectedly early boost for the medicine in lung cancer last week. [nL8N1IE19S...

FDA puts Celgene's multiple cancer trials on hold

Health : Reuters: Health

(Reuters) - Celgene Corp said on Thursday the U.S. Food and Drug Administration had placed a partial clinical hold on the company's five trials and a full clinical hold on one trial.

UCLA opens first engineered blood stem cell clinical trial for cancers with the NY-ESO-1 tumor marker

Health : Newswise Medical News

Scientists at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have initiated a phase 1 clinical trial to test a novel cancer treatment for certain kinds of cancers that have a specific tumor m...

FDA lifts hold on AstraZeneca head and neck cancer trials

Health : Reuters: Health

LONDON (Reuters) - U.S. officials have given a green light for two clinical trials testing AstraZeneca's cancer immunotherapy drug durvalumab in head and neck cancer to resume recruiting patients, lifting a hold imposed following ca...

Novartis says biosimilar rituximab accepted for review by FDA

Health : Reuters: Health

ZURICH (Reuters) - Novartis AG said on Tuesday its biosimilar rituximab to treat blood cancers and immunological diseases such as rheumatoid arthritis was accepted for review by the U.S. Food and Drug Administration (FDA).

Comments


Copyright © 2016 Regator, LLC